Atypical Antipsychotics: Uses, Effectiveness, Side Effects, and What to Expect During Treatment

Atypical antipsychotics — also called second-generation antipsychotics (SGAs) — are a class of psychiatric medications developed in the 1990s and later as alternatives to older, first-generation ("typical") antipsychotics. They are among the most widely prescribed psychiatric medications in the world, used to treat a range of conditions from schizophrenia to bipolar disorder to treatment-resistant depression.

The term "atypical" distinguishes these medications from first-generation antipsychotics like haloperidol and chlorpromazine, which primarily block dopamine D2 receptors and carry a high risk of movement-related side effects. Atypical antipsychotics have a more complex pharmacological profile that generally results in a lower risk of these particular side effects — though they introduce different concerns, particularly metabolic ones.

Mechanism of action: All antipsychotics work at least in part by blocking dopamine D2 receptors in the brain's mesolimbic pathway, which is associated with psychotic symptoms such as hallucinations and delusions. What makes atypical antipsychotics distinct is their additional activity at other receptor sites:

• Serotonin 5-HT2A receptor antagonism: This is the hallmark feature of most atypical antipsychotics. By blocking serotonin receptors in addition to dopamine receptors, these medications are thought to reduce the risk of extrapyramidal symptoms (involuntary movement disorders) and may improve negative symptoms of schizophrenia such as social withdrawal, flat affect, and reduced motivation.
• Variable dopamine binding: Some atypical antipsychotics (notably aripiprazole and brexpiprazole) act as partial agonists at dopamine D2 receptors, meaning they partially stimulate the receptor rather than fully blocking it. This can reduce dopamine activity where it is excessive while preserving it where it is needed.
• Activity at additional receptor sites: Many atypical antipsychotics also interact with histamine, muscarinic, and adrenergic receptors, which contributes to both their therapeutic effects and their side effect profiles.

Commonly prescribed atypical antipsychotics include risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), aripiprazole (Abilify), ziprasidone (Geodon), lurasidone (Latuda), clozapine (Clozaril), paliperidone (Invega), brexpiprazole (Rexulti), cariprazine (Vraylar), and lumateperone (Caplyta). Each has a unique receptor-binding profile that influences its clinical effects and side effects.

Atypical antipsychotics have FDA-approved indications for several psychiatric conditions, and they are also used off-label for others. The range of approved uses has expanded significantly since these medications were first introduced.

Schizophrenia and schizoaffective disorder: This remains the primary indication for which atypical antipsychotics were developed. They are considered first-line treatment for schizophrenia, targeting positive symptoms (hallucinations, delusions, disorganized thinking) and, to a lesser extent, negative symptoms (emotional flatness, social withdrawal, lack of motivation). According to the DSM-5-TR, schizophrenia affects approximately 0.3–0.7% of the population over a lifetime.

Bipolar disorder: Several atypical antipsychotics are FDA-approved for the treatment of acute manic episodes, bipolar depression, or maintenance treatment in bipolar disorder. Olanzapine, quetiapine, aripiprazole, cariprazine, and lurasidone all have approved indications for various phases of bipolar illness.

Major depressive disorder (adjunctive treatment): Aripiprazole, brexpiprazole, quetiapine XR, and cariprazine are approved as add-on treatments for major depressive disorder when antidepressants alone have not provided adequate relief. They are not typically used as standalone antidepressants.

Irritability associated with autism spectrum disorder: Risperidone and aripiprazole are FDA-approved for treating irritability — including aggression, self-injury, and severe tantrums — in children and adolescents with autism spectrum disorder.

Treatment-resistant schizophrenia: Clozapine holds a unique position as the only antipsychotic with demonstrated superior efficacy in treatment-resistant schizophrenia. It is reserved for individuals who have not responded to adequate trials of at least two other antipsychotics.

Off-label uses: Atypical antipsychotics are also prescribed off-label for conditions including anxiety disorders, insomnia, PTSD, borderline personality disorder, delirium, and behavioral disturbances in dementia — though this last use carries an FDA black box warning regarding increased mortality risk in elderly patients with dementia-related psychosis.

Starting an atypical antipsychotic involves a structured process of dose titration, monitoring, and ongoing evaluation. Understanding what to expect can help reduce anxiety about beginning treatment and improve adherence.

Initial evaluation: Before prescribing, a clinician will typically conduct a thorough psychiatric assessment, review medical history, and order baseline laboratory work. This often includes a metabolic panel (fasting blood glucose, lipid profile), body weight and BMI measurement, blood pressure, and sometimes an electrocardiogram (ECG). These baselines are critical because of the metabolic side effects associated with many medications in this class.

Dose titration: Most atypical antipsychotics are started at a low dose and gradually increased — a process called titration. This approach minimizes early side effects such as sedation, dizziness, and gastrointestinal discomfort. The titration schedule varies by medication; some (like quetiapine) require slower increases, while others (like aripiprazole) can be started closer to their therapeutic dose.

Timeline for therapeutic effects: While some effects — particularly sedation and anxiety reduction — can occur within hours to days, the full antipsychotic effect typically takes 2 to 6 weeks to develop. For psychotic symptoms, meaningful improvement often begins within the first 2 weeks, but an adequate trial is generally considered to be at least 4–6 weeks at a therapeutic dose. For depression augmentation, response may take 1–3 weeks after reaching the target dose.

Ongoing monitoring: Regular follow-up is essential. Most clinical guidelines recommend monitoring weight at every visit, metabolic labs at 12 weeks and then annually, and movement disorder assessments using tools like the Abnormal Involuntary Movement Scale (AIMS). Clozapine requires especially rigorous monitoring, including regular absolute neutrophil count (ANC) testing due to the risk of agranulocytosis, a potentially life-threatening drop in white blood cells.

Daily experience: Depending on the specific medication, individuals may notice sedation (especially with quetiapine and olanzapine), increased appetite, improved sleep, reduction in racing thoughts or paranoid thinking, and greater emotional stability. Side effects are most pronounced in the first weeks and often diminish over time, though metabolic effects may worsen with continued use.

Discontinuation: Atypical antipsychotics should never be stopped abruptly without medical supervision. Sudden discontinuation can cause withdrawal symptoms — including insomnia, nausea, psychosis rebound, and dyskinesias — and may precipitate relapse in conditions like schizophrenia. Tapering under clinical guidance is standard practice.

Atypical antipsychotics are among the most extensively studied medications in psychiatry, with decades of randomized controlled trials, meta-analyses, and large-scale pragmatic studies supporting their use.

Schizophrenia: The landmark CATIE trial (Clinical Antipsychotic Trials of Intervention Effectiveness), published in the New England Journal of Medicine in 2005, compared several atypical antipsychotics to the first-generation antipsychotic perphenazine. The study found that the atypical agents were not uniformly superior to the older medication in terms of overall effectiveness, challenging assumptions about the class's advantages. However, olanzapine showed the longest time to discontinuation — a key measure of real-world effectiveness — though this was offset by greater metabolic side effects. Clozapine, studied in Phase 2 of CATIE, demonstrated superior effectiveness for treatment-resistant patients.

A 2019 network meta-analysis published in The Lancet by Huhn and colleagues analyzed 402 randomized trials involving over 53,000 participants with schizophrenia. It found that all antipsychotics were more effective than placebo for reducing overall symptoms, with clozapine, amisulpride, olanzapine, and risperidone showing the largest effect sizes. The study also confirmed substantial differences among individual agents in terms of side effect profiles.

Bipolar disorder: Multiple randomized controlled trials support atypical antipsychotics for acute mania, with response rates typically in the range of 45–65% compared to 25–40% for placebo. For bipolar depression, lurasidone and quetiapine have the strongest evidence, with studies showing significant improvement in depressive symptoms with tolerable side effect profiles.

Adjunctive treatment for depression: Meta-analyses indicate that adding an atypical antipsychotic to an antidepressant produces a modest but statistically significant improvement in treatment-resistant depression. A number needed to treat (NNT) of approximately 7–10 is commonly reported, meaning roughly 1 in 7 to 1 in 10 patients will achieve remission with the addition who would not have done so with the antidepressant alone.

Long-acting injectables (LAIs): Several atypical antipsychotics are available as long-acting injectable formulations (risperidone, paliperidone, aripiprazole). Research consistently shows that LAIs reduce relapse rates and hospitalization compared to oral medications, likely because they eliminate the adherence barrier. A 2017 meta-analysis in JAMA Psychiatry found that LAIs reduced the risk of relapse by approximately 20% relative to oral antipsychotics.

Limitations of the evidence: Much of the clinical trial data comes from industry-sponsored studies, which may introduce publication bias. Trial populations often exclude individuals with comorbid substance use, medical conditions, or suicidality — making generalizability to real-world clinical populations a concern. Additionally, head-to-head comparisons between atypical antipsychotics remain relatively limited.

While atypical antipsychotics generally cause fewer movement-related side effects than first-generation agents, they carry their own significant side effect burden. Understanding these risks is essential for informed decision-making.

Metabolic side effects: This is the most clinically significant concern with many atypical antipsychotics. Weight gain, elevated blood glucose (increasing the risk of type 2 diabetes), and dyslipidemia (abnormal cholesterol and triglyceride levels) are well-documented. The risk varies significantly by medication:

• Highest metabolic risk: Olanzapine and clozapine — associated with average weight gains of 4–10 kg over the first year of treatment
• Moderate metabolic risk: Quetiapine, risperidone, paliperidone
• Lower metabolic risk: Aripiprazole, ziprasidone, lurasidone, cariprazine, brexpiprazole

Sedation and cognitive effects: Quetiapine, olanzapine, and clozapine tend to cause significant sedation, particularly at higher doses. This can impair driving, concentration, and daily functioning. Some individuals also report cognitive blunting or subjective feelings of being "slowed down."

Extrapyramidal symptoms (EPS): Although lower in risk than first-generation antipsychotics, atypical agents can still cause EPS including akathisia (an intensely uncomfortable inner restlessness), dystonia (muscle spasms), parkinsonism (tremor, stiffness), and, with long-term use, tardive dyskinesia (involuntary repetitive movements, often of the face and tongue). Risperidone and paliperidone carry a relatively higher EPS risk within the atypical class, especially at higher doses.

Hyperprolactinemia: Some atypical antipsychotics — particularly risperidone and paliperidone — significantly raise prolactin levels. This can cause menstrual irregularities, breast enlargement or discharge (in any sex), sexual dysfunction, and over the long term, potentially reduced bone density.

Cardiovascular effects: QTc prolongation (a change in heart rhythm that can, in rare cases, lead to dangerous arrhythmias) is a concern with some agents, particularly ziprasidone. Orthostatic hypotension (a sudden drop in blood pressure upon standing) is common in the early stages of treatment with quetiapine, clozapine, and risperidone.

Clozapine-specific risks: Clozapine requires special mention due to the risk of agranulocytosis (occurring in approximately 1–2% of patients), which necessitates mandatory blood monitoring through the Clozapine REMS program. Clozapine also carries risks of myocarditis, seizures (dose-dependent), and severe constipation that can, in rare cases, become life-threatening.

Black box warnings: The FDA has issued black box warnings for atypical antipsychotics regarding (1) increased mortality in elderly patients with dementia-related psychosis and (2) increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking these medications for certain conditions.

Atypical antipsychotics are prescription medications that should be prescribed and managed by a clinician with expertise in psychiatric pharmacology. The type of provider you need depends on your condition, the complexity of your treatment, and your access to care.

Psychiatrists are the specialists most commonly associated with prescribing and managing antipsychotic medications. They have completed medical school followed by a residency in psychiatry, providing them with deep training in psychopharmacology. For complex presentations — such as treatment-resistant schizophrenia, clozapine management, or multiple psychiatric comorbidities — a psychiatrist is typically the most appropriate provider.

Psychiatric nurse practitioners (PMHNPs) are advanced practice registered nurses with specialized training in psychiatric care. In many states, they have independent prescribing authority and manage the full spectrum of psychiatric medications, including atypical antipsychotics. PMHNPs have become increasingly important in addressing the shortage of psychiatrists, particularly in underserved areas.

Primary care physicians sometimes prescribe atypical antipsychotics, particularly for conditions like adjunctive depression treatment or insomnia (off-label). However, for psychotic disorders or complex bipolar presentations, referral to a psychiatric specialist is strongly recommended.

How to find a provider:

• Contact your insurance company for a list of in-network psychiatrists or PMHNPs
• Use directories such as Psychology Today's psychiatrist finder, the SAMHSA treatment locator (findtreatment.gov), or your state's psychiatric medical society
• Ask your primary care physician for a referral
• If you are in a crisis, community mental health centers (CMHCs) often provide psychiatric services on a sliding fee scale
• Telepsychiatry services have expanded access significantly and can be a viable option for those in areas with limited local providers

When meeting with a prescriber for the first time, be prepared to discuss your full psychiatric history, previous medication trials (including doses and reasons for discontinuation), medical history, family psychiatric history, and your goals for treatment.

The cost of atypical antipsychotics varies enormously depending on whether a generic version is available, your insurance coverage, and which specific medication is prescribed.

Generic availability: Several widely used atypical antipsychotics are now available in generic form, including risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone. Generic versions are substantially less expensive, often costing $10–$50 per month with insurance or through discount pharmacy programs. GoodRx and similar prescription discount tools can further reduce out-of-pocket costs.

Brand-name medications: Newer atypical antipsychotics that are still under patent — such as brexpiprazole (Rexulti), cariprazine (Vraylar), and lumateperone (Caplyta) — can cost $1,000–$1,500 or more per month without insurance. Even with insurance, copays for brand-name agents may be $50–$200 or higher, depending on the plan's formulary tier.

Long-acting injectables: Injectable formulations like paliperidone palmitate (Invega Sustenna/Trinza) and aripiprazole lauroxil (Aristada) are significantly more expensive, often ranging from $1,000–$3,000+ per injection before insurance. However, many insurance plans, including Medicaid, do cover these formulations, particularly for individuals with schizophrenia.

Patient assistance programs: Most pharmaceutical manufacturers offer patient assistance programs (PAPs) for individuals who are uninsured or underinsured. These programs can provide medication at no cost or significantly reduced cost. NeedyMeds.org and RxAssist.org maintain searchable databases of available programs.

Insurance and formulary issues: Insurance plans often use step therapy or prior authorization requirements, meaning you may need to try a less expensive medication first before a more costly one is covered. Understanding your plan's formulary — the list of covered medications organized by cost tiers — can help you and your prescriber make informed choices.

Community mental health centers: For individuals with serious mental illness, community mental health centers often provide comprehensive psychiatric care on a sliding fee scale, including medication management. Many centers participate in the 340B Drug Pricing Program, which allows them to obtain medications at significantly reduced costs and pass those savings on to patients.

Depending on the condition being treated, several alternatives or complementary approaches to atypical antipsychotics exist. The appropriateness of alternatives varies greatly by diagnosis and severity.

First-generation (typical) antipsychotics: For schizophrenia and acute psychosis, first-generation agents like haloperidol and fluphenazine remain effective options. They carry a higher risk of extrapyramidal symptoms and tardive dyskinesia but a lower risk of metabolic side effects. They are also generally less expensive. For some individuals, a first-generation antipsychotic may be the preferred choice based on their side effect profile and clinical response.

Mood stabilizers: For bipolar disorder, lithium and anticonvulsants such as valproate (Depakote), lamotrigine (Lamictal), and carbamazepine offer alternatives to atypical antipsychotics. Lithium remains the gold standard for bipolar maintenance treatment, with strong evidence for reducing both manic and depressive episodes as well as suicidality. Lamotrigine is particularly effective for preventing bipolar depression.

Antidepressants: For major depressive disorder, optimizing antidepressant therapy — including switching medications, increasing doses, or combining two antidepressants — is typically attempted before adding an atypical antipsychotic. Other augmentation strategies include lithium augmentation, thyroid hormone augmentation, and buspirone addition.

Psychotherapy: For many conditions, evidence-based psychotherapy is an important component of treatment, whether used alongside or — in some cases — instead of medication:

• Cognitive behavioral therapy for psychosis (CBTp) has moderate evidence for reducing distress associated with psychotic symptoms and improving functioning, though it is not a replacement for antipsychotic medication in most cases of schizophrenia
• Dialectical behavior therapy (DBT) is the treatment of choice for borderline personality disorder, a condition for which antipsychotics are sometimes used off-label
• Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are first-line treatments for depression and can sometimes reduce the need for medication augmentation

Newer treatments: Emerging approaches include pimavanserin (a selective serotonin inverse agonist approved for Parkinson's disease psychosis), xanomeline-trospium (Cobenfy, a muscarinic agonist approved in 2024 for schizophrenia that works through an entirely non-dopaminergic mechanism), and various forms of neuromodulation such as transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT), the latter of which is highly effective for treatment-resistant conditions including psychotic depression and catatonia.

Important note: For schizophrenia and schizoaffective disorder, antipsychotic medication remains the cornerstone of treatment. While psychosocial interventions and lifestyle modifications are valuable adjuncts, discontinuing antipsychotic medication without medical guidance significantly increases the risk of relapse. Any changes to medication should be made collaboratively with a prescribing clinician.

If you are experiencing symptoms that may be associated with a condition for which atypical antipsychotics are prescribed, professional evaluation is the essential first step. The following signs warrant prompt clinical attention:

• Psychotic symptoms: Hearing voices, seeing things that others do not see, beliefs that feel absolutely real but that others find strange or implausible, or a sense that your thoughts are being controlled or broadcast
• Severe mood episodes: Periods of dramatically elevated mood with decreased sleep, racing thoughts, impulsive behavior, or grandiosity (possible mania), or profound depression unresponsive to standard treatment
• Disorganized thinking or behavior: Difficulty maintaining coherent thoughts, unusual speech patterns, or behavior that is confusing to those around you
• Significant functional decline: Withdrawal from relationships, inability to maintain work or school performance, or neglect of self-care

If you are currently taking an atypical antipsychotic, seek immediate medical attention if you experience:

• High fever, muscle rigidity, and confusion (possible neuroleptic malignant syndrome, a rare but life-threatening reaction)
• Uncontrollable movements of the face, tongue, or limbs
• Signs of severe allergic reaction
• Significant suicidal thoughts or plans
• Symptoms of diabetes (excessive thirst, frequent urination, unexplained weight loss) developing during treatment

If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988, or go to your nearest emergency room. For non-emergency concerns about your medication, contact your prescribing clinician's office — most have protocols for addressing medication questions between appointments.